Jiri J. Frohlich

Q: What Schools Are Affiliated With Jiri J. Frohlich

Jiri J. Frohlich is affiliated with the following schools: University of British Columbia, Kumamoto University

Jiri J. Frohlich's AcademicInfluence.com Rankings

Jiri J. Frohlich

Philosophy

#8248

World Rank

#11590

Historical Rank

Logic

#5282

World Rank

#6669

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Jiri J. Frohlich's Degrees

Doctorate Medicine University of Zurich
PhD Cardiology University of Zurich

Why Is Jiri J. Frohlich Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jiri J. Frohlich's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients (1994) (3667)
Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency (1999) (1742)
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. (2001) (1629)
The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). (2001) (935)
2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. (2009) (789)
Effective exercise modality to reduce insulin resistance in women with type 2 diabetes. (2003) (509)
Visceral adipose tissue accumulation differs according to ethnic background: results of the Multicultural Community Health Assessment Trial (M-CHAT). (2007) (509)
Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment (2003) (486)
Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty‐person/ten‐country panel (2006) (478)
The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. (1997) (372)
Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. (2003) (362)
The prognostic importance of endothelial dysfunction and carotid atheroma burden in patients with coronary artery disease. (2003) (340)
Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. (2006) (336)
Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. (2000) (329)
Fractional esterification rate of cholesterol and ratio of triglycerides to HDL-cholesterol are powerful predictors of positive findings on coronary angiography. (2003) (288)
Effects of dietary phytosterols on cholesterol metabolism and atherosclerosis: clinical and experimental evidence. (1999) (280)
Homozygous Tangier disease and cardiovascular disease. (1994) (251)
Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias. (2000) (226)
Proatherogenic and antiatherogenic effects of probucol and phytosterols in apolipoprotein E-deficient mice: possible mechanisms of action. (1999) (192)
Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition (2011) (189)
Effect of a dietary portfolio of cholesterol-lowering foods given at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia: a randomized controlled trial. (2011) (186)
Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016). (2016) (186)
Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. (2011) (181)
Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography (2011) (177)
Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia. (1991) (171)
Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. (2013) (169)
Pathophysiology of apolipoprotein E deficiency in mice: relevance to apo E‐related disorders in humans (2001) (151)
"Tall oil"-derived phytosterols reduce atherosclerosis in ApoE-deficient mice. (1997) (142)
Phenotypic variation in heterozygous familial hypercholesterolemia: a comparison of Chinese patients with the same or similar mutations in the LDL receptor gene in China or Canada. (1998) (138)
Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. (1999) (137)
Myeloperoxidase and C-reactive protein have combined utility for long-term prediction of cardiovascular mortality after coronary angiography. (2010) (132)
Markedly accelerated catabolism of apolipoprotein A-II (ApoA-II) and high density lipoproteins containing ApoA-II in classic lecithin: cholesterol acyltransferase deficiency and fish-eye disease. (1994) (132)
Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study). (2004) (124)
Incidence of pancreatitis, secondary causes, and treatment of patients referred to a specialty lipid clinic with severe hypertriglyceridemia: a retrospective cohort study (2011) (123)
Cerebrotendinous xanthomatosis: a rare disease with diverse manifestations. (2002) (121)
High frequency of mutations in the human lipoprotein lipase gene in pregnancy-induced chylomicronemia: possible association with apolipoprotein E2 isoform. (1994) (121)
DNA polymorphisms in and around the Apo-A1-CIII genes and genetic hyperlipidemias. (1987) (118)
Modification of the relationship between simple anthropometric indices and risk factors by ethnic background. (2003) (113)
Advances in Experimental Dyslipidemia and Atherosclerosis (2001) (110)
Glomerular disease in hypercholesterolemic guinea pigs: a pathogenetic study. (1988) (109)
Homocyst(e)ine and coronary artery disease. Clinical evidence and genetic and metabolic background. (1997) (107)
Triglycerides and small dense LDL: the twin Achilles heels of the Friedewald formula. (2003) (107)
Visceral Adipose Tissue, a Potential Risk Factor for Carotid Atherosclerosis: Results of the Multicultural Community Health Assessment Trial (M-CHAT) (2007) (105)
The Extensive Lifestyle Management Intervention (ELMI) following cardiac rehabilitation trial. (2003) (98)
The effects of age, smoking, and alcohol on routine laboratory tests. (1981) (95)
The Extensive Lifestyle Management Intervention (ELMI) after cardiac rehabilitation: a 4-year randomized controlled trial. (2006) (92)
Risk of Premature Atherosclerotic Disease in Patients With Monogenic Versus Polygenic Familial Hypercholesterolemia. (2019) (92)
Canadian Cardiovascular Society position statement on familial hypercholesterolemia. (2014) (91)
APOA5 gene polymorphism modulates levels of triglyceride, HDL cholesterol and FERHDL but is not a risk factor for coronary artery disease. (2004) (89)
The relationship between simple anthropometric indices and C-reactive protein: ethnic and gender differences. (2003) (89)
Vascular Calcifications in Homozygote Familial Hypercholesterolemia (2008) (87)
Oxidized low-density lipoprotein in experimental focal glomerulosclerosis. (1993) (86)
Cholesterol esterification rates in very low density lipoprotein- and low density lipoprotein-depleted plasma. Relation to high density lipoprotein subspecies, sex, hyperlipidemia, and coronary artery disease. (1991) (84)
Lecithin: cholesterol acyltransferase (LCAT) deficiency and risk of vascular disease: 25 year follow-up. (2004) (81)
Plasma lipoprotein abnormalities in heterozygotes for familial lecithin:cholesterol acyltransferase deficiency. (1988) (81)
The relationship between waist circumference and metabolic risk factors: cohorts of European and Chinese descent. (2002) (79)
Patients with apoE3 deficiency (E2/2, E3/2, and E4/2) who manifest with hyperlipidemia have increased frequency of an Asn 291-->Ser mutation in the human LPL gene. (1995) (76)
The association between triglyceride to high-density-lipoprotein cholesterol ratio and insulin resistance in a multiethnic primary prevention cohort. (2012) (76)
Cholesterol esterification rate in plasma depleted of very low and low density lipoproteins is controlled by the proportion of HDL2 and HDL3 subclasses: study in hypertensive and normal middle-aged and septuagenarian men. (1992) (76)
Intraobserver and interobserver reliability of waist circumference and the waist-to-hip ratio. (2001) (74)
Efficacy of a Therapeutic Lifestyle Change/Step 2 diet in moderately hypercholesterolemic middle-aged and elderly female and male subjects. (2002) (73)
A review on lecithin:cholesterol acyltransferase deficiency. (2015) (73)
Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. (2000) (73)
Decreased Skeletal Muscle Mitochondrial DNA in Patients Treated with High‐Dose Simvastatin (2007) (69)
Lipoprotein(a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia. (2005) (69)
Coronary artery disease in patients at low risk--apolipoprotein AI as an independent risk factor. (2001) (66)
Relative value of multiple plasma biomarkers as risk factors for coronary artery disease and death in an angiography cohort (2006) (65)
Hypertriglyceridemic hyperapoB in type 2 diabetes. (2002) (65)
Dietary sitostanol reduces plaque formation but not lecithin cholesterol acyl transferase activity in rabbits. (1998) (64)
Gene-environment interaction in the conversion of a mild-to-severe phenotype in a patient homozygous for a Ser172-->Cys mutation in the lipoprotein lipase gene. (1993) (64)
Implementing phytosterols into medical practice as a cholesterol-lowering strategy: overview of efficacy, effectiveness, and safety. (2014) (63)
The impact of dietary changes and dietary supplements on lipid profile. (2011) (62)
Phenotypic heterogeneity of sitosterolemia Published, JLR Papers in Press, September 16, 2004. DOI 10.1194/jlr.M400310-JLR200 (2004) (61)
Cardiovascular risk and atherosclerosis prevention. (2013) (61)
Understanding the mechanism of LCAT reaction may help to explain the high predictive value of LDL/HDL cholesterol ratio. (1998) (60)
Canned Soup Consumption and Urinary Bisphenol A : A Randomized Crossover Trial (2011) (59)
Detection of early atherosclerosis with B mode carotid ultrasonography: assessment of a new quantitative approach. (1999) (59)
Rationale for and outline of the recommendations of the Working Group on Hypercholesterolemia and Other Dyslipidemias: interim report. Dyslipidemia Working Group of Health Canada. (1998) (58)
Plasma lipoproteins and lecithin:cholesterol acyltransferase distribution in patients on dialysis. (1984) (58)
Can measurement of serum apolipoprotein B replace the lipid profile monitoring of patients with lipoprotein disorders? (2002) (57)
Effects of alcohol on plasma lipoprotein metabolism. (1996) (57)
Lipoprotein lipase and apoE polymorphisms: relationship to hypertriglyceridemia during pregnancy. (2001) (56)
Circulating surfactant protein-D and the risk of cardiovascular morbidity and mortality. (2011) (56)
Clinical usefulness of lipid ratios to identify men and women with metabolic syndrome: a cross-sectional study (2014) (55)
Image in cardiovascular medicine. Aortic xanthomatosis with coronary ostial occlusion in a child homozygous for a nonsense mutation in ABCG8. (2003) (54)
Lack of regression of atherosclerotic lesions in phytosterol-treated apo E-deficient mice. (1999) (52)
Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus. (2004) (52)
Advances in understanding of the role of lecithin cholesterol acyltransferase (LCAT) in cholesterol transport. (1999) (51)
Simplified Canadian Definition for Familial Hypercholesterolemia. (2018) (50)
Gender differences in plasma levels of lipoprotein (a) in patients with angiographically proven coronary artery disease. (2004) (48)
Lp(a) concentration and apo(a) isoform size. Relation to the presence of coronary artery disease in familial hypercholesterolemia. (1994) (48)
Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes. (2004) (45)
The concept of precision extended to the atherogenic index of plasma. (2008) (44)
Histologic, hematologic, and biochemical characteristics of apo E-deficient mice: effects of dietary cholesterol and phytosterols. (1999) (44)
Are Cardiovascular Disease and Osteoporosis Directly Linked? (2004) (43)
Severe familial HDL deficiency in French-Canadian kindreds. Clinical, biochemical, and molecular characterization. (1995) (43)
Appropriateness of current thresholds for obesity-related measures among Aboriginal people (2007) (42)
Laboratory standardization of a large international clinical trial: the DAIS experience. DAIS Project Group. Diabetes Atherosclerosis Intervention Study. (2000) (42)
The Role of Risk Factors in the Development of Atherosclerosis (2001) (40)
Risk stratification of patients with familial hypercholesterolemia in a multi-ethnic cohort (2014) (40)
Lipoprotein-X stimulates monocyte chemoattractant protein-1 expression in mesangial cells via nuclear factor-kappa B. (2001) (40)
Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin. (2007) (39)
[The new atherogenic plasma index reflects the triglyceride and HDL-cholesterol ratio, the lipoprotein particle size and the cholesterol esterification rate: changes during lipanor therapy]. (2000) (39)
Erythrocyte membrane alterations in lecithin:cholesterol acyltransferase deficiency. (1978) (39)
Asymptomatic hypothyroidism and statin-induced myopathy. (2007) (38)
Role of plant sterols in cholesterol lowering. (2004) (37)
Common mutations in the lipoprotein lipase gene (LPL): effects on HDL-cholesterol levels in a Chinese Canadian population. (2001) (37)
Role of lecithin:cholesterol acyltransferase and apolipoprotein A-I in cholesterol esterification in lipoprotein-X in vitro. (1995) (37)
Impact of hydrogenated fat on high density lipoprotein subfractions and metabolism. (2001) (37)
Niacin: from mechanisms of action to therapeutic uses. (2010) (35)
Ascertainment Bias in the Association Between Elevated Lipoprotein(a) and Familial Hypercholesterolemia. (2020) (35)
Therapeutic Role (2008) (34)
Common problems in the management of hypertriglyceridemia. (2002) (34)
The effect of a dietary portfolio compared to a DASH-type diet on blood pressure. (2015) (33)
Hepatic cholesterol and bile acid synthesis, low-density lipoprotein receptor function, and plasma and fecal sterol levels in mice: effects of apolipoprotein E deficiency and probucol or phytosterol treatment. (2001) (33)
Recommendations for the Management of Dyslipidemia and the Prevention of Cardiovascular Disease: 200 (2003) (33)
Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol. (2004) (32)
Assessment of novel risk factors in patients at low risk for cardiovascular events based on Framingham risk stratification. (2003) (32)
Promotion of sterol efflux and net transport by apolipoprotein E in lecithin:cholesterol acyltransferase deficiency. (1982) (32)
Apolipoprotein B versus lipoprotein lipids: vital lessons from the AFCAPS/TexCAPS trial. (2001) (32)
Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia. (1994) (32)
The cornea in familial high density lipoprotein deficiency, tangier disease (1991) (32)
Effect of immunosuppressive therapy, serum creatinine, and time after transplant on plasma total homocysteine in patients following heart transplantation. (1999) (31)
Positive association of adiponectin with soluble vascular cell adhesion molecule sVCAM-1 levels in patients with vascular disease or dyslipidemia. (2008) (30)
Response of cholesterol synthesis to cholesterol feeding in men with different apolipoprotein E genotypes. (1993) (29)
Atherogenic lipoprotein profile in families with and without history of early myocardial infarction. (2001) (29)
Specificity of the commonly used enzymatic assay for plasma cholesterol determination (2002) (29)
Hypoalphalipoproteinemia resembling fish eye disease. (2009) (29)
Measurement of fractional esterification rate of cholesterol in plasma depleted of apoprotein B containing lipoprotein: methods and normal values. (1996) (29)
Lecithin: cholesterol acyl transferase (LCAT). (1982) (29)
Dietary measures and exercise training contribute to improvement of endothelial function and atherosclerosis even in patients given intensive pharmacologic therapy. (2006) (29)
Lipoprotein(a) the Insurgent: A New Insight into the Structure, Function, Metabolism, Pathogenicity, and Medications Affecting Lipoprotein(a) Molecule (2020) (28)
Lipoprotein (a), an independent cardiovascular risk marker (2016) (28)
Relationship between cholesteryl ester transfer activity and high density lipoprotein composition in hyperlipidemic patients. (1989) (27)
A randomized controlled trial of an extensive lifestyle management intervention (ELMI) following cardiac rehabilitation: study design and baseline data (2002) (27)
Lipid transfer proteins, hypertriglyceridemia, and reduced high-density lipoprotein cholesterol. (1991) (27)
Structural and functional assessment of high-density lipoprotein heterogeneity. (1994) (27)
Fish odour syndrome (2011) (27)
Monocytes and macrophages in focal glomerulosclerosis in Zucker rats. (1991) (26)
Apolipoprotein B versus LDL-cholesterol: Association with other risk factors for atherosclerosis. (2009) (26)
Lecithin:cholesterol acyltransferase in familial HDL deficiency (Tangier disease). (1988) (26)
Dietary sitostanol and campestanol: Accumulation in the blood of humans with sitosterolemia and xanthomatosis and in rat tissues (2005) (26)
Familial high‐density‐lipoprotein deficiency causing corneal opacities (fish eye disease) in a family of Dutch descent (1992) (26)
The clinical significance of serum high density lipoproteins. (1989) (25)
Dyslipidaemia and coagulation defects of insulin resistance. (2000) (25)
Lipid screening to prevent coronary artery disease: a quantitative evaluation of evolving guidelines. (2000) (24)
Clinical, Biochemical, and Molecular Characterization of Novel Mutations in ABCA1 in Families with Tangier Disease. (2014) (24)
Effect of labeling of plasma lipoproteins with [(3)H]cholesterol on values of esterification rate of cholesterol in apolipoprotein B-depleted plasma. (2000) (23)
Attainment of Recommended Lipid Targets in Patients With Familial Hypercholesterolemia: Real-World Experience With PCSK9 Inhibitors. (2018) (23)
Risk factors for atherosclerosis in survivors of myocardial infarction and their spouses: comparison to controls without personal and family history of atherosclerosis. (2001) (23)
Plant sterols and their role in combined use with statins for lipid lowering. (2005) (22)
Lecithin: cholesterol acyltransferase (LCAT) deficiency syndromes. (1986) (22)
Fractional Esterification Rate of HDL Particles in Patients With Type 2 Diabetes: Relation to coronary heart disease risk factors (1998) (22)
Cholesteryl ester transfer activity in plasma measured by using solid-phase-bound high-density lipoprotein. (1987) (22)
Association of skin cholesterol content, measured by a noninvasive method, with markers of inflammation and Framingham risk prediction. (2002) (21)
Lipid altering or antioxidant vitamins for patients with coronary disease and very low HDL cholesterol? The HDL-Atherosclerosis Treatment Study Design. (1998) (21)
Increased prevalence of clinical and subclinical atherosclerosis in patients with damaging mutations in ABCA1 or APOA1. (2017) (21)
Contemporary Trends in the Management and Outcomes of Patients With Familial Hypercholesterolemia in Canada: A Prospective Observational Study. (2017) (21)
Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients (2015) (21)
Detection of heterozygotes for familial lecithin: cholesterol acyltransferase (LCAT) deficiency. (1982) (21)
Assays of lecithin cholesterol acyltransferase (LCAT). (1998) (20)
Extensive lifestyle management intervention following cardiac rehabilitation: pilot study. (2001) (20)
Differential effects of simvastatin and atorvastatin on high‐density lipoprotein cholesterol and apolipoprotein A‐I are consistent across hypercholesterolemic patient subgroups (2003) (19)
Unusual renal biopsy findings in a patient with familial lecithin:cholesterol acyltransferase deficiency. (1982) (19)
Targeted next-generation sequencing to diagnose disorders of HDL cholesterol[S] (2015) (19)
Simvastatin plus niacin protect against atherosclerosis progression and clinical events in coronary artery disease patients with metabolic syndrome (2002) (18)
Characterization of subspecies of apolipoprotein A-I-containing lipoprotein in homozygotes for familial lecithin:cholesterol acyltransferase deficiency. (1994) (18)
Consumption of a dietary portfolio of cholesterol lowering foods improves blood lipids without affecting concentrations of fat soluble compounds (2014) (16)
Comparison of gemfibrozil and clofibrate on serum lipids in familial combined hyperlipidemia. A randomized placebo-controlled, double-blind, crossover clinical trial. (1988) (16)
A kindred with fish eye disease, corneal opacities, marked high-density lipoprotein deficiency, and statin therapy. (2014) (16)
Differences in cardiovascular risks in the aboriginal and non-aboriginal people living in Bella Coola, British Columbia. (2005) (16)
Marked effects of extreme levels of lipoprotein(a) on estimation of low-density lipoprotein cholesterol. (2014) (16)
Cholesterol and triglyceride fatty acid synthesis in apolipoprotein E2-associated hyperlipidemia. (1992) (16)
Coronary atherosclerosis in anorexia nervosa. (2003) (16)
Study of the components of reverse cholesterol transport in lecithin:cholesterol acyltransferase deficiency. (1987) (15)
Old and new risk factors for atherosclerosis and development of treatment recommendations (2002) (15)
Comparison of the short term efficacy and tolerability of lovastatin and simvastatin in the management of primary hypercholesterolemia. (1993) (15)
The pathology of cornea in Tangier disease (familial high density lipoprotein deficiency). (1996) (15)
Extended interactive voice response telephony (IVR) for relapse prevention after smoking cessation using varenicline and IVR: a pilot study (2013) (14)
Case series of type III hyperlipoproteinemia in children (2011) (14)
Erythrocyte membrane alterations and plasma lipids in patients with chylomicronemia and in Tangier disease. (1986) (13)
Complete Apo AI deficiency in an Iraqi Mandaean family: case studies and review of the literature. (2010) (13)
Interaction of high density lipoprotein with adipocytes in a new patient with Tangier disease. (1987) (13)
Statin-Associated Muscle Adverse Events: Update for clinicians. (2016) (13)
Subclinical atherosclerosis in subjects with family history of premature coronary artery disease. (2008) (13)
Lecithin:cholesterol acyltransferase deficiency. (1988) (13)
Chemical precipitation of apolipoprotein B-containing lipoproteins facilitates determination of LDL particle size. (2000) (12)
Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on sterol absorption in hypercholesterolemic subjects. (1999) (12)
A muclticenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia (1990) (12)
Use of metabolic drugs and fish oil in HIV‐positive patients with metabolic complications and associations with dyslipidaemia and treatment targets (2007) (12)
Relation of cholesterol esterification rate to the plasma distribution of high-density lipoprotein subclasses in normal and hypertensive women. (1995) (12)
Lipoproteins and homocyst(e)ine as risk factors for atherosclerosis: assessment and treatment. (1995) (12)
Association between apolipoprotein E phenotype and endogenous cholesterol synthesis as measured by deuterium uptake. (1991) (11)
Statins but not fibrates improve the atherogenic to anti-atherogenic lipoprotein particle ratio: a randomized crossover study (2008) (11)
Comparison of apolipoprotein B and plasma lipids as targets for lipid lowering treatment. (2005) (11)
Study of erythrocytes in a hereditary hemolytic syndrome (HHS): comparison with erythrocytes in lecithin:cholesterol acyltransferase (LCAT) deficiency. (2009) (11)
Ancel Keys and the lipid hypothesis: From early breakthroughs to current management of dyslipidemia (2009) (11)
Regional and national familial hypercholesterolemia registries: present international application, importance, and needs for Canada. (2013) (11)
Low prevalence of type 2 diabetes mellitus among patients with high levels of high-density lipoprotein cholesterol. (2013) (11)
Effective treatment of hyperhomocysteinemia in heart transplant recipients with and without renal failure. (2001) (10)
Handbook of Lipoprotein Testing, 2nd Edition by (2001) (10)
Extreme hypertriglyceridemia following intravenous heparin infusion. (2008) (9)
Statin therapy and the management of acute coronary syndromes. (2003) (9)
Action of a microbial glycerophospholipid:cholesterol acyltransferase on plasma from normal and LCAT-deficient subjects. (1984) (9)
Purification of biologically active apolipoproteins by chromatofocussing. (1986) (9)
The British Columbia Familial Hypercholesterolemia Registry (2013) (8)
Positive association of adiponectin with soluble thrombomodulin, von Willebrand factor and soluble VCAM-1 in dyslipidemic subjects. (2013) (8)
Dramatic lowering of very high Lp(a) in response to niacin. (2014) (8)
Poster abstractStructural and functional assessment of HDL heterogeneity (1994) (8)
Erythrocyte alterations in praseodymium-induced lecithin:cholesterol acyltransferase (LCAT) deficiency in the rat: comparison with familial LCAT deficiency in man. (1981) (8)
Familial defective apolipoprotein B-100 in hypercholesterolemic Chinese Canadians: identification of a unique haplotype of the apolipoprotein B-100 allele. (1997) (7)
Cholesteryl ester transfer activity in plasma of patients with familial high-density lipoprotein deficiency. (1988) (7)
Assessment of atherogenic profile of plasma using estimation of cholesterol esterification rate in apolipoprotein B depleted plasma (FERHDL) and Logarithmically transformed ratio of triglyceride/HDL-cholesterol (1999) (7)
Cholesterol-Lowering Foods and Reduction in Serum Cholesterol Levels—Reply (2011) (7)
Effect of cyclosporin A on serum lipids in primary biliary cirrhosis patients. (1989) (7)
Predictors of Metabolic Syndrome in Participants of a Cardiac Rehabilitation Program (2012) (7)
Statins and bones. (2001) (6)
Dietary supplementation with fish gelatine modifies nutrient intake and leads to sex-dependent responses in TAG and C-reactive protein levels of insulin-resistant subjects (2012) (6)
Hepatic lipase deficiency in a Middle-Eastern-Arabic male (2010) (6)
Efficacy and safety of fluvastatin in hyperlipidaemic patients with non-insulin-dependent diabetes mellitus. (1994) (6)
Statin resistant dyslipidemia in a patient treated with amiodarone (2011) (6)
Use of ezetimibe results in more patients reaching lipid targets without side effects (2014) (5)
Serial measurement of plasma cholesterol and lecithin:cholesterol acyl transferase activity in adults receiving total parenteral nutrition. (1985) (5)
The analysis by Manuel and colleagues creates controversy with headlines, not data (2005) (5)
Characterization of subspecies of lipoprotein containing apolipoprotein A-I in heterozygotes for familial lecithin:cholesterol acyltransferase deficiency. (1995) (5)
Detection of vesicular lipoproteins in lecithin:cholesterol acyltransferase-deficient plasma by 1H-NMR spectroscopy. (1989) (5)
Liver biochemistry abnormalities in a quaternary care lipid clinic database. (2008) (4)
Apoprotein A-I and lecithin: cholesterol acyltransferase in a patient with Tangier disease. (1986) (4)
2.P.195 Gender differences in prediction of coronary artery disease (CAD) by plasma lipoproteins, LCAT measurements (1997) (3)
Urinary proteins in a patient with Tangier disease. (1985) (3)
Follow-up of type III hyperlipoproteinaemia in a child (2001) (3)
Evidence for impaired cellular cholesterol removal mediated by apo A-I containing lipoproteins in patients with familial lecithin: cholesterol acyltransferase deficiency. (1994) (3)
Effectiveness of Colestipol Tablets vs Granules in Patients with Moderate to Severe Hypercholesterolaemia (1995) (3)
Lipid and lipoprotein changes during the seven days off oral contraception in women using two triphasic preparations. (1988) (3)
Exercise in a Healthy Heart Program: A Cohort Study (2013) (3)
Erythrocyte abnormalities in a hypoalphalipoproteinemia syndrome resembling fish eye disease (1988) (3)
Lack of benefit in treating high homocysteine levels with vitamins (2007) (3)
Lipids and cardiovascular diseases. (1999) (3)
Dysbetalipoproteinemia and clomipramine. (2005) (3)
Safety of statin therapy in patients with mitochondrial diseases. (2013) (3)
The role of apoproteins in disorders of lipoprotein metabolism. (1989) (3)
Analysis of familial hypoalphalipoproteinemia syndromes (1992) (3)
Lecithin:cholesterol acyltransferase activity in plasma of patients with multiple sclerosis. (1983) (2)
CARDIOVASCULAR RISK ASSESSMENT BY ATHEROGENIC INDEX OF PLASMA [LOG(TG/HDL-C)] (2008) (2)
Carotid ultrasound, coronary calcium, and dyslipidemia patterns in the MESA (Multi-Ethnic Study of Atherosclerosis) cohort. (2010) (2)
Coronary artery calcium findings in asymptomatic subjects with family history of premature coronary artery disease (2012) (2)
High resolution lh nmr spectra of human apolipoprotein C-iii2 using DPC to model the lipoprotein environment (1997) (2)
Workshop abstractCholesterol esterification in plasma and the risk of coronary artery disease (1994) (1)
W16-O-004 Comparison of apolipoprotein B and plasma lipids as targets for lipid lowering treatment (2005) (1)
Gender differences in serum levels of Lp(a) in coronary artery disease patients (2000) (1)
Abstract PR-04: Blood lipid and lipoprotein levels and the risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (2010) (1)
Pharmacology of drugs used to treat smoking cessation and obesity (2008) (1)
Reaching target lipid levels in patients at high risk of cardiovascular event: the experience of a Canadian tertiary care lipid clinic. (2007) (1)
THE EXTENSIVE LIFESTYLE MANAGEMENT INTERVENTION (ELMI) TRIAL: PILOT STUDY. (1999) (1)
Relation of anthropometric parameters to the functional assessment of HDL particle size in three ethnic cohorts. (2006) (1)
Hereditary high phosphatidylcholine hemolytic anemia: report of a new family and review of the literature. (1990) (1)
COMPLETE APO AI DEFICIENCY IN A FAMILY FROM IRAQ (2008) (1)
Effects of dietary phytosterols on cholesterol metabolism and atherosclerosis: The reply (2000) (1)
The Atherosclerosis Reversal Clinic: the way of the future. (2001) (1)
Abstract 9959: An Intensive Lifestyle Modification Program Reduces the Number of Component Factors in Subjects With Metabolic Syndrome (2012) (1)
Cholesterol efflux capacity and atherosclerosis. (2011) (1)
Blood cholesterol is causally related to atherosclerosis. (1994) (1)
W16-P-046 Reaching target lipid levels in high risk patients: The experience of a Canadian tertiary care lipid clinic (2005) (1)
Use of once-weekly statin in combination with ezetimibe in a patient with mitochondrial disease (2012) (1)
Comparative efficacy and safety study of pravastatin and gemfibrozil in patients with primary hypercholesterolemia (1994) (1)
Paediatric type III dyslipidaemia: a case of vanishing hyperlipidaemia (2012) (1)
Lipid clinics/cardiovascular risk reduction clinics: current state and future consideration. (2001) (1)
Abstract 243: Canadian Familial Hypercholesterolemia Registry (2014) (1)
Hepatic Lipase Deficiency in a Middle-Eastern/Arabic Male∗ (2010) (1)
Running title : Goal-inhibiting statin intolerance (2016) (0)
Update on the Familial Hypercholesterolemia Canada (FH Canada) Registry (2018) (0)
PARTICIPATION BARRIERS TO CARDIAC REHABILITATION (1996) (0)
W12-P-017 Lipoprotein(A) level is an independent predictor of age of first cardiovascular event in patients with heterozygous familial hypercholesterolemia (2005) (0)
UvA-DARE (Digital Academic Repository) Age and residuel cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes (2016) (0)
Molecular diagnosis of abnormalities of HDL cholesterol by targeted next-generation sequencing (2015) (0)
Cholestyramine tablets, a new option in the treatment of hypercholesterolemia (1994) (0)
A patient’s informative mistake: niacin is very effective in correcting dyslipidaemia (2010) (0)
MEASUREMENT OF CIRCULATING PREGNANCY-ASSOCIATED PLASMA PROTEIN A (CPAPP-A) IDENTIFIES PATIENTS WITH ACUTE CORONARY SYNDROMES (2010) (0)
TARGETED NEXT-GENERATION SEQUENCING TO DIAGNOSE ABNORMALITIES OF HDL CHOLESTEROL (2015) (0)
Abstract: P820 APOLIPOPROTEIN B VERSUS LDL-CHOLESTEROL: ASSOCIATION WITH OTHER RISK FACTORS FOR ATHEROSCLEROSIS (2009) (0)
PO14-383 IMPACT OF FAMILY HISTORY OF PREMATURE CORONARY ARTERY DISEASE ON CAROTID ULTRASOUND TRAITS AND TOTAL HOMOCYSTEINE LEVELS (2007) (0)
Lipid metabolism in non-endocrine disease (1990) (0)
HYPERHOMOCYST(E)INEMIA AS A RISK FACTOR FOR CORONARY ARTERY DISEASE: WHO IS AT RISK: 11 (1997) (0)
1.P.155 Effects of cardiac rehabilitation program on plasma lipoprotein-cholesterol levels in obese man (1997) (0)
P41 CHARACTERIZATION OF PATIENTS WITH VERY HIGH PLASMA HDL-CHOLESTEROL, WITH AND WITHOUT VASCULAR PATHOLOGY (2010) (0)
Insulin resistance (1996) (0)
Thyroid Peroxidase Antibody Predicts Antenatal Complications (2000) (0)
Targeted next-generation sequencing to diagnose disorders of HDL cholesterol patient-oriented and epidemiological research (2020) (0)
1.P.108 Effects of probucol on the antioxidant system in apo E-deficient mice (1997) (0)
Can Cholesterol Ester Transfer Protein (CETP) Taq1B genotype alter the impact of standardized cardiac rehabilitation program (CRP) on lipid risk markers (2000) (0)
Monogenic Familial Hypercholesterolemia, Polygenic Hypercholesterolemia, And The Risk Of Premature Atherosclerotic Cardiovascular Disease (2019) (0)
W10-P-012 Relation of FER-HDL and AIP to clinical and laboratory parameters in hats (2005) (0)
Canadian Cardiovascular Society Position Statement onFamilial Hypercholesterolemia (2014) (0)
2.P.63 Tolerability of phytosterols in apo E-deficient mice (1997) (0)
REACHING TARGET LIPID LEVELS AND RESERVES IN HYPOLIPIDEMIC THERAPY IN PATIENTS AT VERY HIGH RISK OF CARDIOVASCULAR EVENTS - TWO CENTRES EXPERIENCE: PP.32.94 (2011) (0)
Apolipoprotein-AI — An independent risk factor for atherosclerosis in low risk populations (1999) (0)
Relative value of plasma nitrotyrosine for predicting mortality in patients with coronary artery diseases (2007) (0)
Risk factors for atherosclerosis in survivors of myocardial infarction and their spouses: Comparison with spousal pairs without personal and family history of atherosclerosis (2000) (0)
Clinical significance of serum HDL cholesterol. (1989) (0)
CETP IN RARE DYSLIPIDEMIAS (2009) (0)
Appropriate treatment of dyslipidaemia in angiographically defined British Columbians (2000) (0)
251 BIOMARKERS OF OXIDATIVE STRESS: RELATIVE PREDICTIVE VALUE FOR CARDIOVASCULAR MORTALITY. (2006) (0)
Abstract 4164: Decreased Skeletal Muscle Mitochondrial DNA in Patients on High-Dose Simvastatin Therapy (2006) (0)
Replacement of usual lipid lowering treatment by atorvastatin: Effect on plasma lipid levels (2000) (0)
Effect of diets enriched in saturated and hydrogenated fat on HDL metabolism (2000) (0)
655 The association between the triglyceride-to-high-density-lipoprotein ratio and metabolic syndrome in four ethnic groups (2011) (0)
Plasma cholesterol and red blood cell 2,3‐diphosphoglycerate (1982) (0)
EffectofaDietaryPortfolioofCholesterol-Lowering Foods Given at 2 Levels of Intensity of Dietary Advice on Serum Lipids in Hyperlipidemia A Randomized Controlled Trial (2011) (0)
Familial combined hyperlipidemia and insulin resistance. (2001) (0)
Modified lipoproteins and cardiovascular risk. (2001) (0)
Oxidized low-density lipoprotein in experimental focal glomeruloscierosis (2015) (0)
246 Improvement in Metabolic Syndrome Component Factors Following An Intensive Lifestyle Modification Program (2012) (0)
Extensive lifestyle management intervention following cardiac rehabilitation: Study design (2000) (0)
W02-P-015 Novel cardiovascular risk factors in individuals with family history of premature atherosclerotic disease (2005) (0)
Symposium - Is medical treatment of coronary artery disease superior to revasculation procedures?, Vancouver, BC, Canada, 31 May 1997 (1998) (0)
Abstract 1095: Vascular Calcifications in Homozygote Familial Hypercholesterolemia: the Canadian Experience (2007) (0)
Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients (2015) (0)
Dysbetalipoproteinemia and clomipramine. Author's reply (2005) (0)
CONTEMPORARY TRENDS IN THE MANAGEMENT AND OUTCOMES OF PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA IN CANADA (2016) (0)
1.P.70 Dietary supplementation with phytosterols or probucol alters fecal excretion of sterols in apo E-knockout mice (1997) (0)
arotid Ultrasound , oronary Calcium , and yslipidemia Patterns in he MESA ( Multi-Ethnic Study f Atherosclerosis ) Cohort (0)
Comparison of cholesterol-lowering effects of hydrogenated vs unhydrogenated tall oil phytosterols in apo E-KO mice (2000) (0)
CAD RISK FACTORS IN HYPERALPHALIPOPROTEINEMIA (2008) (0)
Lipoprotein-X stimulates MCP-1 expression in mesangial cells: a possible role in monocyte infiltration in familial LCAT deficiency (2000) (0)
Abstract 6266: Targeting Metabolic Syndrome: A New Approach to Intensive Lifestyle Intervention and Self Management Support (2008) (0)
1.P.265 Phenotypic variation in familial hypercholesterolemia: A comparison of Chinese patients heterozygous for the same or similar mutations in the low density lipoprotein-receptor gene living in China or Canada (1997) (0)
A Rare Disease With Diverse Manifestations (2016) (0)
2.P.246 Methylentetrahydrofolate reductase genotypes in young survivors of myocardial infarction (1997) (0)
ENHANCED RELATIVE BENEFIT OF CARDIAC REHAB IN PATIENTS WITH LOW BASELINE FITNESS LEVELS. (1999) (0)
Age and residuel cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA 1 heterozygotes (2000) (0)
Cardiovascular risk in patients with type 2 diabetes (2005) (0)
Cost effective diagnosis and treatment of atherosclerosis. Canadian Cardiovascular Society. (1995) (0)
The association between triglyceride to high-density-lipoprotein ratio and insulin resistance in a multi-ethnic primary prevention cohort (2011) (0)
Canadian Definition for Familial Hypercholesterolemia (2018) (0)
Measurement of apolipoprotein B by radial immunodiffusion. (1983) (0)
PO13-350 COMPARISON OF CARDIOVASCULAR RISK ASSESSMENT AND LDL CHOLESTEROL TARGET VALUES: VARIOUS GUIDELINES VERSUS CLINICAL PRACTICE (2007) (0)
Development and Validation of a Dietary Portfolio Score for use Among Hypercholesterolemic Individuals (2015) (0)
W12-P-035 Homocysteine and IL-6 are independent predictors of total and cardiovascular mortality in an angiography cohort (2005) (0)
Increased Prevalence of Clinical and Sub-Clinical Atherosclerosis in Individuals With Damaging Mutations in ABCA1 and APOA1 (2017) (0)
Reply: To PMID 25110227. (2014) (0)
Effects of Multidisciplinary Cardiac Rehabilitation Program on Plasma Lipid Profile (1999) (0)
29 familial combined hyperlipoproteinemia (FCH) classified according to apolipoprotein E (APO E) phenotype (1985) (0)
The Canadian lipid guidelines are difficult to model quantitatively. (2008) (0)
Comprehensive care for the prevention and reduction of diabetes: a self-management focused program (2009) (0)
Th-P15:53 Atherogenic index of plasma (AIP) is an effective predictor of cardiovascular risk (2006) (0)
Visceral adipose tissue accumulation differs according to ethnic background : results of the Multicultural Community Health Assessment Trial ( M-CHAT ) 1 3 (2007) (0)
Effects of combination of tall oil sterols and n-3 fatty acids on atherosclerotic lesion development in cholesterol-fed (0.2% w/w) apo E-KO mice (2000) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Jiri J. Frohlich?

Jiri J. Frohlich is affiliated with the following schools: